ArticleFrontiers in reproductive health2026
Intracavernosal UC-MSC secretome therapy for severe erectile dysfunction: a clinical anatomy pilot study with elastography and Doppler assessment.
Article in Frontiers in reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Erectile dysfunction (ED) is often treated with phosphodiesterase type 5 inhibitors (PDE5i). However, some patients do not respond effectively to this treatment, making regenerative therapy a potential alternative. This study aims to evaluate the safety and efficacy of umbilical cord-derived mesenchymal stem cell (UC-MSC) secretome in patients with severe ED who are unresponsive to sildenafil therapy. Methods: In this clinical anatomy pilot study, 15 male patients with severe ED unresponsive to sildenafil were administered intracavernosal injections of 0.5 cc of UC-MSC secretome into each corpus cavernosum at the Andrology Clinic of RSUD Dr. Soetomo (Dr. Soetomo General Academic Hospital) in Surabaya, Indonesia, between January 2024 and May 2024 and at RS Universitas Indonesia between January 2025 and May 2025. Therapy safety was evaluated based on local bleeding, hematoma, infection, and pain, while efficacy was measured using the Erection Hardness Score (EHS), International Index of Erectile Function-5 (IIEF-5), reports of morning erections, stretched penis length (SPL), flaccid penis length (FPL), penis circumference, and Penile Doppler Color Ultrasound to evaluate peak systolic velocity (PSV), resistive index (RI), intima-media thickness (IMT), shear wave elastography (SWE), and strain ratio (SR). Results: Significant improvements were observed in EHS, IIEF-5, morning erections, SPL, FPL, penis circumference, PSV, SWE, and SR after therapy. Pain was temporary and subsided within a few minutes. No significant differences in local bleeding, hematoma, and infection were observed. There was a difference in the IMT of the cavernous artery that was not statistically significant, while RI could not be analyzed. Discussion: These findings suggest that UC-MSC secretome is safe and effective as an alternative therapy for severe ED unresponsive to sildenafil, as evidenced by significant changes in EHS, IIEF-5, morning erections, SPL, FPL, penis circumference, PSV, SWE, and SR post- therapy with the potential for temporary pain. Further research is needed to support the development of regenerative therapy for the treatment of ED unresponsive to conventional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.